Eli Lilly signs up to $1.12 billion deal with private gene-editing firm Seamless U.S. drugmaker Eli Lilly signed an agreement worth up to $1.12 billion with Seamless Therapeutics, the Germany-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results